Menu Search
Equities

Hyenergy SA

WQ3:FRA

Hyenergy SA

Actions
  • Price (EUR)0.582
  • Today's Change0.006 / 1.04%
  • Shares traded--
  • 1 Year change-14.91%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

  • Revenue in PLN (TTM)462.00k
  • Net income in PLN-6.12m
  • Incorporated2010
  • Employees27.00
  • Location
    Hyenergy SAul. Sciegiennego 20POZNAN 60-128PolandPOL
  • Phone+48 616468585
  • Fax+48 616232526
  • Websitehttp://www.inno-gene.pl/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IGN:WSE since
announced		Transaction
value
Hydrogenium PSAAnnounced03 Sep 202403 Sep 2024Announced4.57%25.88m
Data delayed at least 15 minutes, as of Nov 13 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.